Efficacy and safety of netakimab therapy in patients with moderate to severe psoriasis in real clinical practice
- 作者: Bakulev A.L.1, Pritulo O.A.2, Kuntsevich Z.S.3, Khotko A.A.4, Yunovidova A.A.5, Gorognichev P.V.6, Ziganshin O.R.7, Rudneva N.S.8, Bildyuk E.V.9, Repina T.V.10, Dudko V.Y.11, Maksimova M.D.11
-
隶属关系:
- Central State Medical Academy, Department of Presidential Affairs
- Institute “S.I. Georgievsky Medical Academy” of V.I. Vernadsky Crimean Federal University
- Moscow Regional Research Clinical Institute named after M.F. Vladimirsky
- Clinical Dermatovenereologic Dispensary, Krasnodar
- Skin Clinic of Pierre Volkenshtein
- Nizhny Novgorod Branch of the State Scientific Center of Dermatovenereology and Cosmetology
- Chelyabinsk Regional Clinical Dermatovenereology Dispensary
- Tula Regional Dermatovenereologic Dispensary
- Republican Clinical Skin and Venereal Diseases Dispensary, Kazan
- Clinical Dermatovenereologic Dispensary, Omsk
- City Skin and Venereological Dispensary, Saint Petersburg
- 期: 卷 99, 编号 5 (2023)
- 页面: 84-95
- 栏目: GUIDELINES FOR PRACTITIONERS
- URL: https://ogarev-online.ru/0042-4609/article/view/217605
- DOI: https://doi.org/10.25208/vdv14864
- ID: 217605
如何引用文章
全文:
详细
Rationale. Data from randomized clinical trials (RCTs) may differ from the results of the efficacy and safety of medicines in the conditions of daily work.
Purpose. To obtain data on the long-term efficacy and safety of the use of the genetically engineered biological drug netakimab in real clinical practice.
Methods. In everyday clinical practice, a multicenter non-interventional observational study BCD-085-NIS-01 (ORION) was conducted, which involved 260 adult patients with moderate to severe psoriasis.
Results. It was established that the survival rate of genetically engineered biological therapy of netakimab, when analyzing data of 104 weeks of observation, remains high both in bionaive patients and in persons who have previously received treatment for this dermatosis using monoclonal antibodies. The long-term safety profile of netakimab in real clinical practice is comparable to data previously obtained in RCTs and remains favorable for follow-ups up to 2 years.
Conclusion. Therapy with GIBA netakimab using a standard dose of 120 mg and regimen in patients with psoriasis is effective and safe for 104 weeks.
作者简介
Andrey Bakulev
Central State Medical Academy, Department of Presidential Affairs
编辑信件的主要联系方式.
Email: al_ba05@mail.ru
ORCID iD: 0000-0002-1450-4942
SPIN 代码: 6708-7386
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, MoscowOlga Pritulo
Institute “S.I. Georgievsky Medical Academy” of V.I. Vernadsky Crimean Federal University
Email: 55550256@mail.ru
ORCID iD: 0000-0001-6515-1924
SPIN 代码: 2988-8463
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, SimferopolZhanna Kuntsevich
Moscow Regional Research Clinical Institute named after M.F. Vladimirsky
Email: j_s_k@mail.ru
ORCID iD: 0000-0002-7135-9067
SPIN 代码: 5923-4310
MD, Cand. Sci. (Med.)
俄罗斯联邦, MoscowAlkes Khotko
Clinical Dermatovenereologic Dispensary, Krasnodar
Email: alkes@inbox.ru
ORCID iD: 0000-0002-8688-4876
SPIN 代码: 6929-3790
MD, Cand. Sci. (Med.)
俄罗斯联邦, KrasnodarAnastasiya Yunovidova
Skin Clinic of Pierre Volkenshtein
Email: anastasia.yunovidova@gmail.com
ORCID iD: 0000-0002-7986-798X
SPIN 代码: 6883-3022
MD
俄罗斯联邦, Saint PetersburgPavel Gorognichev
Nizhny Novgorod Branch of the State Scientific Center of Dermatovenereology and Cosmetology
Email: gorpav@icloud.com
ORCID iD: 0000-0001-5989-7156
SPIN 代码: 6103-0456
MD, Cand. Sci. (Med.)
俄罗斯联邦, Nizhny NovgorodOleg Ziganshin
Chelyabinsk Regional Clinical Dermatovenereology Dispensary
Email: ziganshin_oleg@mail.ru
ORCID iD: 0000-0002-5857-0319
SPIN 代码: 5339-2533
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, ChelyabinskNatalya Rudneva
Tula Regional Dermatovenereologic Dispensary
Email: Natalya.Rudneva@tularegion.ru
ORCID iD: 0000-0002-0621-5518
SPIN 代码: 1758-2990
MD, Cand. Sci. (Med.)
俄罗斯联邦, ТulaEvgeniya Bildyuk
Republican Clinical Skin and Venereal Diseases Dispensary, Kazan
Email: zhenya-kazan@mail.ru
ORCID iD: 0000-0001-9069-7718
SPIN 代码: 9541-5160
MD, Cand. Sci. (Med.)
俄罗斯联邦, KazanTatiana Repina
Clinical Dermatovenereologic Dispensary, Omsk
Email: t.v.repina@mail.ru
ORCID iD: 0000-0002-4779-9126
SPIN 代码: 3755-8470
MD, Cand. Sci. (Med.)
俄罗斯联邦, OmskValentina Dudko
City Skin and Venereological Dispensary, Saint Petersburg
Email: dudkovalentina@yandex.ru
ORCID iD: 0000-0002-3480-1821
SPIN 代码: 8288-4212
MD, Cand. Sci. (Med.)
俄罗斯联邦, Saint PetersburgMariya Maksimova
City Skin and Venereological Dispensary, Saint Petersburg
Email: maryam5129@gmail.ru
ORCID iD: 0000-0003-4518-0458
SPIN 代码: 7663-8273
Dermatovenerologist
俄罗斯联邦, Saint Petersburg参考
- Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46(1):1–23. doi: 10.1067/mjd.2002.120568
- Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160(4):810–820. doi: 10.1111/j.1476-5381.2010.00702.x
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. doi: 10.1056/NEJMra0804595
- Albanesi C, De Pità O, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol. 2007;25(6):581–588. doi: 10.1016/j.clindermatol.2007.08.013
- Monteleone G, Pallone F, MacDonald TT, Chimenti S, Costanzo A. Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci (Lond). 2011;120(1):1–11. doi: 10.1042/CS20100163
- Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207–1211. doi: 10.1038/sj.jid.5701213
- Ortega C, Fernández AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009;86(2):435–443. doi: 10.1189/JLB.0109046
- Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573–3585. doi: 10.1172/JCI40202
- Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46(1):1–23. doi: 10.1067/mjd.2002.120568
- Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine network in psoriasis. Clin Dermatol. 2007;25(6):568–573. doi: 10.1016/j.clindermatol.2007.08.011
- Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22(8):993–1005. doi: 10.1517/13543784.2013.806483
- Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717–724. doi: 10.1111/j.1365-2133.2012.11099.x
- Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183(6):2593–2603. doi: 10.1084/jem.183.6.2593
- Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–898. doi: 10.1056/NEJMra0707449
- Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol. 2013;146(2):131–139. doi: 10.1016/j.clim.2012.12.004
- Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9):2175–2183. doi: 10.1038/jid.2009.65
- Олисова О.Ю., Анпилогова Е.М. Системная терапия псориаза: от метотрексата до генно-инженерных биологических препаратов. Вестник дерматологии и венерологии. 2020;96(3):7–26. [Olisova OYu, Anpilogova EM. Systemic treatment of psoriasis: from methotrexate to biologics. Vestnik dermatologii i venerologii. 2020;96(3):7–26. (In Russ.)] doi: 10.25208/vdv1162
- Самцов А.В., Хайрутдинов В.Р., Бакулев А.Л., Кубанов А.А., Карамова А.Э., и др. Эффективность и безопасность препарата BCD-085 — оригинального моноклонального антитела против интерлейкина-17 у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Результаты II фазы международного многоцентрового сравнительного рандомизированного двойного слепого плацебо-контролируемого клинического исследования. Вестник дерматологии и венерологии. 2017;5:52–63. [Samtsov AV, Khairutdinov VR, Bakulev AL, Kubanov AA, Karamova AE, et al. Efficacy and safety of BCD-085, a novel IL-17 inhibitor. Results of phase II clinical trial in patients with moderate-to-severe plaque psoriasis. Vestnik Dermatologii i Venerologii. 2017;5:52–63. (In Russ.)] doi: 10.25208/0042-4609-2017-93-5-52-63
- Кубанов А.А., Бакулев А.Л., Самцов А.В., Хайрутдинов В.Р., Соколовский Е.В., Кохан М.М., и др. Нетакимаб — новый ингибитор ИЛ-17а: результаты 12 недель клинического исследования III фазы BCD-085-7/PLANETA у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Вестник дерматологии и венерологии. 2019;95(2):15–28. [Kubanov AA, Bakulev AL, Samtsov AV, Khairutdinov VR, Sokolovskiy EV, Kokhan MM, et al. Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis. Vestnik dermatologii i venerologii. 2019;95(2):15–28. (In Russ.)] doi: 10.25208/0042-4609-2019-95-2-15-28
- Бакулев А.Л., Самцов А.В., Кубанов А.А., Хайрутдинов В.Р., Кохан М.М., Артемьева А.В., и др. Долгосрочная эффективность и безопасность препарата нетакимаб у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Результаты открытого продленного клинического исследования II фазы BCD-085-2-ext. Вестник дерматологии и венерологии. 2019;95(3):54–64. [Bakulev AL, Samtsov AV, Kubanov AA, Khairutdinov VR, Kokhan MM, Artemyeva AV, et al. Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext. Vestnik dermatologii i venerologii 2019;95(3):54–64. (In Russ.)] doi: 10.25208/0042-4609-2019-95-3-54-64
- Пуч Л., Бакулев А.Л., Кохан М.М., Самцов А.В., Хайрутдинов В.Р., Морозова М.А., и др. Эффективность и безопасность нового моноклонального антитела к ИЛ-17 нетакимаба у пациентов со среднетяжелым и тяжелым бляшечным псориазом. Результаты 54-недельного рандомизированного двойного слепого плацебо-контролируемого клинического исследования PLANETA. Вестник дерматологии и венерологии 2021;97(4):80–91. [Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, et al. Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. Vestnik dermatologii i venerologii. 2021;97(4):80–91. (In Russ.)] doi: 10.25208/vdv1251
- Бакулев А.Л., Самцов А.В., Соколовский Е.В., Кохан М.М., Хобейш М.М., Хайрутдинов В.Р., и др. Эффективность и безопасность двухлетней терапии нетакимабом у пациентов со среднетяжелым и тяжелым бляшечным псориазом в рамках рандомизированного двойного слепого плацебо-контролируемого клинического исследования BCD-085-7/PLANETA. Вестник дерматологии и венерологии. 2022;98(2):42–52. [Bakulev AI, Samtsov AV, Sokolovskiy EV, Kokhan MM, Khobeish MM, Khairutdinov VR, et al. Efficacy and safety profile of 2-year netakimab treatment in patients with moderate-to-severe plaque psoriasis in terms of the randomized double-blind placebo-controlled BCD-085-7/PLANETA clinical trial. Vestnik dermatologii i venerologii. 2022;98(2):42–52. (In Russ.)] doi: 10.25208/vdv1306
- Круглова Л.С., Бакулев А.Л., Коротаева Т.В., Лила А.М., Переверзина Н.О. Псориаз. М.: ГЭОТАР-Медиа, 2022. 320 с. [Kruglova LS, Bakulev AL, Korotaeva TV, Lila AM, Pereverzina NO. Psoriasis. M.: GEOTAR-Media; 2022. 320 p. (In Russ.)]
- Кубанов А.А., Бакулев А.Л., Карамова А.Э., Притуло О.А., Аршинский М.И., Знаменская Л.Ф., и др. Псориаз. Федеральные клинические рекомендации. М., 2020. [Kubanov AA, Bakulev AL, Karamova AE, Pritulo OA, Arshinsky MI, Znamenskaya LF, et al. Psoriasis. Federal clinical guidelines. Moscow; 2020. (In Russ.)]. URL: minzdrav.gov.ru
- Kubanov A, Bakulev A, Fitileva T, Novoderezhkina E, Gilloteau I, Tian H, et al. Disease Burden and Treatment Patterns of Psoriasis in Russia: A Real-World Patient and Dermatologist Survey. Dermatol Ther (Heidelb). 2018;8(4):581–592. doi: 10.1007/s13555-018-0262-1
- Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. J Dermatolog Treat. 2020;31(4):317–318. doi: 10.1080/09546634.2020.1742438
- Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;20(10):3098–3102. doi: 10.1111/jocd.14381
补充文件
